Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Executive Director, GxP Quality & Compliance is a senior leadership role responsible for defining and executing the global compliance strategy across clinical development programs and commercial products. This role will ensure adherence to applicable regulatory requirements, industry standards, and company policies governing GxP activities. The role provides strategic oversight of inspection readiness, quality systems, compliance risk management, supplier oversight and compliance, and enterprise-wide GxP initiatives. In this role, you will shape enterprise quality strategy, influence executive decision-making, and build a world-class compliance organization that supports sustainable growth and operational excellence. This position serves as a key advisor to senior leadership on global compliance policy and strategy and reports to the Vice President, Global Quality.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive